Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 294

1.

Monitoring real-time hormone release kinetics via high-content 3-D imaging of compensatory endocytosis.

Tarasov AI, Galvanovskis J, Rorsman O, Hamilton A, Vergari E, Johnson PRV, Reimann F, Ashcroft FM, Rorsman P.

Lab Chip. 2018 Aug 7. doi: 10.1039/c8lc00417j. [Epub ahead of print]

PMID:
30083680
2.

Magnesium deficiency prevents high-fat-diet-induced obesity in mice.

Kurstjens S, van Diepen JA, Overmars-Bos C, Alkema W, Bindels RJM, Ashcroft FM, Tack CJJ, Hoenderop JGJ, de Baaij JHF.

Diabetologia. 2018 Jul 9. doi: 10.1007/s00125-018-4680-5. [Epub ahead of print]

PMID:
29987474
3.

Influences: Find a friend.

Ashcroft FM.

J Gen Physiol. 2018 Jul 2;150(7):895-896. doi: 10.1085/jgp.201812123. Epub 2018 Jun 21. No abstract available.

PMID:
29930195
4.

Permanent neonatal diabetes: combining sulfonylureas with insulin may be an effective treatment.

Misra S, Vedovato N, Cliff E, De Franco E, Hattersley AT, Ashcroft FM, Oliver NS.

Diabet Med. 2018 Jun 13. doi: 10.1111/dme.13758. [Epub ahead of print]

PMID:
29896782
5.

Binding of sulphonylureas to plasma proteins - A KATP channel perspective.

Proks P, Kramer H, Haythorne E, Ashcroft FM.

PLoS One. 2018 May 17;13(5):e0197634. doi: 10.1371/journal.pone.0197634. eCollection 2018.

6.

Cardiac Dysfunction and Metabolic Inflexibility in a Mouse Model of Diabetes Without Dyslipidemia.

Rohm M, Savic D, Ball V, Curtis MK, Bonham S, Fischer R, Legrave N, MacRae JI, Tyler DJ, Ashcroft FM.

Diabetes. 2018 Jun;67(6):1057-1067. doi: 10.2337/db17-1195. Epub 2018 Apr 2.

PMID:
29610263
7.

Pancreatic β-Cell Electrical Activity and Insulin Secretion: Of Mice and Men.

Rorsman P, Ashcroft FM.

Physiol Rev. 2018 Jan 1;98(1):117-214. doi: 10.1152/physrev.00008.2017. Review.

8.

FTO demethylase activity is essential for normal bone growth and bone mineralization in mice.

Sachse G, Church C, Stewart M, Cater H, Teboul L, Cox RD, Ashcroft FM.

Biochim Biophys Acta. 2018 Mar;1864(3):843-850. doi: 10.1016/j.bbadis.2017.11.027. Epub 2017 Dec 2. No abstract available.

9.

Fumarate Hydratase Deletion in Pancreatic β Cells Leads to Progressive Diabetes.

Adam J, Ramracheya R, Chibalina MV, Ternette N, Hamilton A, Tarasov AI, Zhang Q, Rebelato E, Rorsman NJG, Martín-Del-Río R, Lewis A, Özkan G, Do HW, Spégel P, Saitoh K, Kato K, Igarashi K, Kessler BM, Pugh CW, Tamarit-Rodriguez J, Mulder H, Clark A, Frizzell N, Soga T, Ashcroft FM, Silver A, Pollard PJ, Rorsman P.

Cell Rep. 2017 Sep 26;20(13):3135-3148. doi: 10.1016/j.celrep.2017.08.093.

10.

Is Type 2 Diabetes a Glycogen Storage Disease of Pancreatic β Cells?

Ashcroft FM, Rohm M, Clark A, Brereton MF.

Cell Metab. 2017 Jul 5;26(1):17-23. doi: 10.1016/j.cmet.2017.05.014. Review.

11.

An ABCC8 Nonsense Mutation Causing Neonatal Diabetes Through Altered Transcript Expression.

Flanagan SE, Dũng VC, Houghton JAL, De Franco E, Ngoc CTB, Damhuis A, Ashcroft FM, Harries LW, Ellard S.

J Clin Res Pediatr Endocrinol. 2017 Sep 1;9(3):260-264. doi: 10.4274/jcrpe.4624. Epub 2017 Jun 30.

12.

Functional identification of islet cell types by electrophysiological fingerprinting.

Briant LJ, Zhang Q, Vergari E, Kellard JA, Rodriguez B, Ashcroft FM, Rorsman P.

J R Soc Interface. 2017 Mar;14(128). pii: 20160999. doi: 10.1098/rsif.2016.0999.

13.

Neonatal Diabetes and the KATP Channel: From Mutation to Therapy.

Ashcroft FM, Puljung MC, Vedovato N.

Trends Endocrinol Metab. 2017 May;28(5):377-387. doi: 10.1016/j.tem.2017.02.003. Epub 2017 Mar 3. Review.

14.

Hyperglycaemia induces metabolic dysfunction and glycogen accumulation in pancreatic β-cells.

Brereton MF, Rohm M, Shimomura K, Holland C, Tornovsky-Babeay S, Dadon D, Iberl M, Chibalina MV, Lee S, Glaser B, Dor Y, Rorsman P, Clark A, Ashcroft FM.

Nat Commun. 2016 Nov 24;7:13496. doi: 10.1038/ncomms13496.

15.

Pancreatic β-Cells Express the Fetal Islet Hormone Gastrin in Rodent and Human Diabetes.

Dahan T, Ziv O, Horwitz E, Zemmour H, Lavi J, Swisa A, Leibowitz G, Ashcroft FM, In't Veld P, Glaser B, Dor Y.

Diabetes. 2017 Feb;66(2):426-436. doi: 10.2337/db16-0641. Epub 2016 Nov 18.

16.

β-Cell dysfunction in diabetes: a crisis of identity?

Brereton MF, Rohm M, Ashcroft FM.

Diabetes Obes Metab. 2016 Sep;18 Suppl 1:102-9. doi: 10.1111/dom.12732. Review.

17.

Correction to 'Running out of time: the decline of channel activity and nucleotide activation in adenosine triphosphate-sensitive K-channels'.

Proks P, Puljung MC, Vedovato N, Sachse G, Mulvaney R, Ashcroft FM.

Philos Trans R Soc Lond B Biol Sci. 2016 Sep 5;371(1702). pii: 20160330. doi: 10.1098/rstb.2016.0330. No abstract available.

18.

Running out of time: the decline of channel activity and nucleotide activation in adenosine triphosphate-sensitive K-channels.

Proks P, Puljung MC, Vedovato N, Sachse G, Mulvaney R, Ashcroft FM.

Philos Trans R Soc Lond B Biol Sci. 2016 Aug 5;371(1700). pii: 20150426. doi: 10.1098/rstb.2015.0426. Review. Erratum in: Philos Trans R Soc Lond B Biol Sci. 2016 Sep 5;371(1702). pii: 20160330. doi: 10.1098/rstb.2016.0330.

19.

Neonatal diabetes caused by a homozygous KCNJ11 mutation demonstrates that tiny changes in ATP sensitivity markedly affect diabetes risk.

Vedovato N, Cliff E, Proks P, Poovazhagi V, Flanagan SE, Ellard S, Hattersley AT, Ashcroft FM.

Diabetologia. 2016 Jul;59(7):1430-1436. doi: 10.1007/s00125-016-3964-x. Epub 2016 Apr 27.

20.

Successful transfer to sulfonylureas in KCNJ11 neonatal diabetes is determined by the mutation and duration of diabetes.

Babiker T, Vedovato N, Patel K, Thomas N, Finn R, Männikkö R, Chakera AJ, Flanagan SE, Shepherd MH, Ellard S, Ashcroft FM, Hattersley AT.

Diabetologia. 2016 Jun;59(6):1162-6. doi: 10.1007/s00125-016-3921-8. Epub 2016 Mar 31.

21.

The Nucleotide-Binding Sites of SUR1: A Mechanistic Model.

Vedovato N, Ashcroft FM, Puljung MC.

Biophys J. 2015 Dec 15;109(12):2452-60. doi: 10.1016/j.bpj.2015.10.026. Review.

22.

The value of in vitro studies in a case of neonatal diabetes with a novel Kir6.2-W68G mutation.

O'Connell SM, Proks P, Kramer H, Mattis KK, Sachse G, Joyce C, Houghton JA, Ellard S, Hattersley AT, Ashcroft FM, O'Riordan SM.

Clin Case Rep. 2015 Oct;3(10):884-7. doi: 10.1002/ccr3.370. Epub 2015 Sep 8.

23.

Systemic Administration of Glibenclamide Fails to Achieve Therapeutic Levels in the Brain and Cerebrospinal Fluid of Rodents.

Lahmann C, Kramer HB, Ashcroft FM.

PLoS One. 2015 Jul 30;10(7):e0134476. doi: 10.1371/journal.pone.0134476. eCollection 2015.

24.

Q&A: insulin secretion and type 2 diabetes: why do β-cells fail?

Cantley J, Ashcroft FM.

BMC Biol. 2015 May 16;13:33. doi: 10.1186/s12915-015-0140-6. No abstract available.

25.

FTO influences adipogenesis by regulating mitotic clonal expansion.

Merkestein M, Laber S, McMurray F, Andrew D, Sachse G, Sanderson J, Li M, Usher S, Sellayah D, Ashcroft FM, Cox RD.

Nat Commun. 2015 Apr 17;6:6792. doi: 10.1038/ncomms7792.

26.

Pharmacological inhibition of FTO.

McMurray F, Demetriades M, Aik W, Merkestein M, Kramer H, Andrew DS, Scudamore CL, Hough TA, Wells S, Ashcroft FM, McDonough MA, Schofield CJ, Cox RD.

PLoS One. 2015 Apr 1;10(4):e0121829. doi: 10.1371/journal.pone.0121829. eCollection 2015.

27.

Sulfonylureas suppress the stimulatory action of Mg-nucleotides on Kir6.2/SUR1 but not Kir6.2/SUR2A KATP channels: a mechanistic study.

Proks P, de Wet H, Ashcroft FM.

J Gen Physiol. 2014 Nov;144(5):469-86. doi: 10.1085/jgp.201411222.

28.

Fetal macrosomia and neonatal hyperinsulinemic hypoglycemia associated with transplacental transfer of sulfonylurea in a mother with KCNJ11-related neonatal diabetes.

Myngheer N, Allegaert K, Hattersley A, McDonald T, Kramer H, Ashcroft FM, Verhaeghe J, Mathieu C, Casteels K.

Diabetes Care. 2014 Dec;37(12):3333-5. doi: 10.2337/dc14-1247. Epub 2014 Sep 17.

29.

Na+ current properties in islet α- and β-cells reflect cell-specific Scn3a and Scn9a expression.

Zhang Q, Chibalina MV, Bengtsson M, Groschner LN, Ramracheya R, Rorsman NJ, Leiss V, Nassar MA, Welling A, Gribble FM, Reimann F, Hofmann F, Wood JN, Ashcroft FM, Rorsman P.

J Physiol. 2014 Nov 1;592(21):4677-96. doi: 10.1113/jphysiol.2014.274209. Epub 2014 Aug 28.

30.

Reversible changes in pancreatic islet structure and function produced by elevated blood glucose.

Brereton MF, Iberl M, Shimomura K, Zhang Q, Adriaenssens AE, Proks P, Spiliotis II, Dace W, Mattis KK, Ramracheya R, Gribble FM, Reimann F, Clark A, Rorsman P, Ashcroft FM.

Nat Commun. 2014 Aug 22;5:4639. doi: 10.1038/ncomms5639.

31.

Changes in gene expression associated with FTO overexpression in mice.

Merkestein M, McTaggart JS, Lee S, Kramer HB, McMurray F, Lafond M, Boutens L, Cox R, Ashcroft FM.

PLoS One. 2014 May 19;9(5):e97162. doi: 10.1371/journal.pone.0097162. eCollection 2014.

32.

A mutation causing increased KATP channel activity leads to reduced anxiety in mice.

Lahmann C, Clark RH, Iberl M, Ashcroft FM.

Physiol Behav. 2014 Apr 22;129:79-84. doi: 10.1016/j.physbeh.2014.02.031. Epub 2014 Feb 25.

33.

Type 2 diabetes and congenital hyperinsulinism cause DNA double-strand breaks and p53 activity in β cells.

Tornovsky-Babeay S, Dadon D, Ziv O, Tzipilevich E, Kadosh T, Schyr-Ben Haroush R, Hija A, Stolovich-Rain M, Furth-Lavi J, Granot Z, Porat S, Philipson LH, Herold KC, Bhatti TR, Stanley C, Ashcroft FM, In't Veld P, Saada A, Magnuson MA, Glaser B, Dor Y.

Cell Metab. 2014 Jan 7;19(1):109-21. doi: 10.1016/j.cmet.2013.11.007. Epub 2013 Dec 12.

34.

Role of KATP channels in glucose-regulated glucagon secretion and impaired counterregulation in type 2 diabetes.

Zhang Q, Ramracheya R, Lahmann C, Tarasov A, Bengtsson M, Braha O, Braun M, Brereton M, Collins S, Galvanovskis J, Gonzalez A, Groschner LN, Rorsman NJ, Salehi A, Travers ME, Walker JN, Gloyn AL, Gribble F, Johnson PR, Reimann F, Ashcroft FM, Rorsman P.

Cell Metab. 2013 Dec 3;18(6):871-82. doi: 10.1016/j.cmet.2013.10.014.

35.

K(ATP) channels and islet hormone secretion: new insights and controversies.

Ashcroft FM, Rorsman P.

Nat Rev Endocrinol. 2013 Nov;9(11):660-9. doi: 10.1038/nrendo.2013.166. Epub 2013 Sep 17. Review.

36.

A mouse model of human hyperinsulinism produced by the E1506K mutation in the sulphonylurea receptor SUR1.

Shimomura K, Tusa M, Iberl M, Brereton MF, Kaizik S, Proks P, Lahmann C, Yaluri N, Modi S, Huopio H, Ustinov J, Otonkoski T, Laakso M, Ashcroft FM.

Diabetes. 2013 Nov;62(11):3797-806. doi: 10.2337/db12-1611. Epub 2013 Jul 31.

37.

Molecular mechanism of sulphonylurea block of K(ATP) channels carrying mutations that impair ATP inhibition and cause neonatal diabetes.

Proks P, de Wet H, Ashcroft FM.

Diabetes. 2013 Nov;62(11):3909-19. doi: 10.2337/db13-0531. Epub 2013 Jul 8.

38.

Mouse Models of β-cell KATP Channel Dysfunction.

Brereton MF, Ashcroft FM.

Drug Discov Today Dis Models. 2013 Summer;10(2):e101-e109. doi: 10.1016/j.ddmod.2013.02.001.

39.

Gain-of-function mutations in the K(ATP) channel (KCNJ11) impair coordinated hand-eye tracking.

McTaggart JS, Jenkinson N, Brittain JS, Greeley SA, Hattersley AT, Ashcroft FM.

PLoS One. 2013 Apr 23;8(4):e62646. doi: 10.1371/journal.pone.0062646. Print 2013.

40.

Switching to sulphonylureas in children with iDEND syndrome caused by KCNJ11 mutations results in improved cerebellar perfusion.

Fendler W, Pietrzak I, Brereton MF, Lahmann C, Gadzicki M, Bienkiewicz M, Drozdz I, Borowiec M, Malecki MT, Ashcroft FM, Mlynarski WM.

Diabetes Care. 2013 Aug;36(8):2311-6. doi: 10.2337/dc12-2166. Epub 2013 Mar 5.

41.

Autosomal dominant hypercalciuria in a mouse model due to a mutation of the epithelial calcium channel, TRPV5.

Loh NY, Bentley L, Dimke H, Verkaart S, Tammaro P, Gorvin CM, Stechman MJ, Ahmad BN, Hannan FM, Piret SE, Evans H, Bellantuono I, Hough TA, Fraser WD, Hoenderop JG, Ashcroft FM, Brown SD, Bindels RJ, Cox RD, Thakker RV.

PLoS One. 2013;8(1):e55412. doi: 10.1371/journal.pone.0055412. Epub 2013 Jan 30.

42.

Role for the obesity-related FTO gene in the cellular sensing of amino acids.

Gulati P, Cheung MK, Antrobus R, Church CD, Harding HP, Tung YC, Rimmington D, Ma M, Ron D, Lehner PJ, Ashcroft FM, Cox RD, Coll AP, O'Rahilly S, Yeo GS.

Proc Natl Acad Sci U S A. 2013 Feb 12;110(7):2557-62. doi: 10.1073/pnas.1222796110. Epub 2013 Jan 28.

43.

Adult onset global loss of the fto gene alters body composition and metabolism in the mouse.

McMurray F, Church CD, Larder R, Nicholson G, Wells S, Teboul L, Tung YC, Rimmington D, Bosch F, Jimenez V, Yeo GS, O'Rahilly S, Ashcroft FM, Coll AP, Cox RD.

PLoS Genet. 2013;9(1):e1003166. doi: 10.1371/journal.pgen.1003166. Epub 2013 Jan 3.

44.

Tetrameric structure of SUR2B revealed by electron microscopy of oriented single particles.

Fotinou C, Aittoniemi J, de Wet H, Polidori A, Pucci B, Sansom MS, Vénien-Bryan C, Ashcroft FM.

FEBS J. 2013 Feb;280(4):1051-63. doi: 10.1111/febs.12097. Epub 2013 Jan 27.

45.

A universally conserved residue in the SUR1 subunit of the KATP channel is essential for translating nucleotide binding at SUR1 into channel opening.

de Wet H, Shimomura K, Aittoniemi J, Ahmad N, Lafond M, Sansom MS, Ashcroft FM.

J Physiol. 2012 Oct 15;590(20):5025-36. doi: 10.1113/jphysiol.2012.236075. Epub 2012 Jul 16.

46.

Diabetes mellitus and the β cell: the last ten years.

Ashcroft FM, Rorsman P.

Cell. 2012 Mar 16;148(6):1160-71. doi: 10.1016/j.cell.2012.02.010. Review.

47.

Mice expressing a human K(ATP) channel mutation have altered channel ATP sensitivity but no cardiac abnormalities.

Clark R, Männikkö R, Stuckey DJ, Iberl M, Clarke K, Ashcroft FM.

Diabetologia. 2012 Apr;55(4):1195-204. doi: 10.1007/s00125-011-2428-6. Epub 2012 Jan 18.

48.

FTO is expressed in neurones throughout the brain and its expression is unaltered by fasting.

McTaggart JS, Lee S, Iberl M, Church C, Cox RD, Ashcroft FM.

PLoS One. 2011;6(11):e27968. doi: 10.1371/journal.pone.0027968. Epub 2011 Nov 30.

49.

Mutations of the same conserved glutamate residue in NBD2 of the sulfonylurea receptor 1 subunit of the KATP channel can result in either hyperinsulinism or neonatal diabetes.

Männikkö R, Flanagan SE, Sim X, Segal D, Hussain K, Ellard S, Hattersley AT, Ashcroft FM.

Diabetes. 2011 Jun;60(6):1813-22. doi: 10.2337/db10-1583.

50.

A high-throughput assay for modulators of NNT activity in permeabilized yeast cells.

Meadows NA, Saxty B, Albury MS, Kettleborough CA, Ashcroft FM, Moore AL, Cox RD.

J Biomol Screen. 2011 Aug;16(7):734-43. doi: 10.1177/1087057111408088. Epub 2011 May 20.

PMID:
21602486

Supplemental Content

Loading ...
Support Center